Chemodex

Tanshinone I

CHF 54.00
In stock
CDX-T0417-M0055 mgCHF 54.00
CDX-T0417-M02525 mgCHF 217.00
More Information
Product Details
Synonyms Tanshinon I; Tanshinone A; 1,6-Dimethylphenanthro[1,2-b]furan-10,11-dione
Product Type Chemical
Properties
Formula C18H12O3
MW 276.29
CAS 568-73-0
Source/Host Chemicals Isolated from plant source.
Purity Chemicals ≥98% (HPLC)
Appearance Purple-black powder.
Solubility Soluble in DMSO, chloroform or methanol.
Identity Determined by 1H-NMR.
Declaration Manufactured by Chemodex.
Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

InChi Key AIGAZQPHXLWMOJ-UHFFFAOYSA-N
Smiles O=C(C1=C(C2=C3C(C)=CO2)C=CC4=C1C=CC=C4C)C3=O
Shipping and Handling
Shipping AMBIENT
Short Term Storage +20°C
Long Term Storage +4°C
Handling Advice Protect from light and moisture.
Use/Stability Stable for at least 2 years after receipt when stored at +4°C.
Documents
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF
Description

Tanshinone I is a diterpene that has been found in S. miltiorrhiza and has diverse biological activities, including anticancer, antidiabetic, anti-inflammatory, immunosuppressive, anticoagulant and neuroprotective properties. It inhibits proliferation in a variety of cancer cell lines, including KB/VCR, MCF-7/ADR, and K562/A02 multidrug resistance cell lines. It inhibits topoisomerase I- and topoisomerase II-mediated supercoiled DNA relaxation activity. It has been shown to induce apoptosis in several cancer cell lines. It reduces plasma levels of total cholesterol, triglycerides, LDL and nonesterified fatty acids and decreases blood glucose levels in a rat model of type 2 diabetes induced by streptozotocin and a high-fat diet. Tanshinone I reduces the LPS-induced expression of TNF-α, IL-1β, and IL-6 in microglia in vitro. It is neuroprotective in a mouse model of Parkinson‘s disease induced by MPTP.

Product References

(1) J.Y. Kim, et al.; Pharmacol. Toxicol. 92, 195 (2003) | (2) I.T. Nizamutdinova, et al.; Carcinogenesis 29, 1885 (2008) | (3) I.T. Nizamutdinova, et al.; Int. J. Oncol. 33, 485 (2008) | (4) C.Y. Lee, et al.; Mol. Cancer Ther. 7, 3527 (2008) | (5) L. Yang, et al.; PLoS One 8, e80464 (2013) | (6) J.H. Park, et al.; Neurochem. Res. 39, 1300 (2014) | (7) S. Wang, et al.; J. Ethnaopharmacol. 164, 247 (2015) | (8) M.K. Kim, et al.; Fitoterapia 101, 162 (2015) | (9) X. Jing, et al.; Neurochem. Res. 41, 779 (2016) | (10) Y. Wei, et al.; Biomed. Pharmacother. 93, 352 (2017) | (11) Q.-T. Tian, et al.; Biochem. Pharmacol. 156, 255 (2018) | (12) Y. Yan, et al.; Mol. Pharm. 15, 4843 (2018)

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.